Hyperinflation Respiratory Therapies in Cardiac Surgery Patients: A Randomized, Observer-Blinded, Prospective Clinical Trial

What this Trial Is About

Researchers are evaluating three different types of hyperinflation respiratory therapies in patients who have undergone cardiac surgery. The study aims to find out which therapy helps expand the lungs better and may improve lung recovery after surgery. This is important because pain from surgery can limit lung expansion, leading to complications like lung collapse or airway secretion buildup. The trial is a prospective randomized clinical study comparing Intermittent Positive Pressure Breathing (IPPB), Intermittent Positive End Expiratory Pressure (EzPAP), and Metaneb therapies. Participants will be randomly assigned to receive one of the three hyperinflation respiratory therapies. IPPB supports breathing by providing pressure to increase air volume. EzPAP and Metaneb involve breathing against resistance to keep the lungs open longer. Each therapy is given every 4 hours in the intensive care unit, with sessions lasting about 10 to 15 minutes. The total study period lasts about 96 hours after surgery or until the patient is discharged from the ICU. During the study, lung function will be measured daily using a microspirometer, which takes about 5 minutes, to monitor recovery. Researchers will watch for any lung over-expansion risks or typical post-surgery complications, such as pneumothorax, infection, blood changes, or breathing difficulties. The main outcome measured is the change in lung function (FEV1/FVC) up to 96 hours after surgery or until ICU discharge. Participants will be closely monitored throughout their ICU stay for safety and lung recovery progress.

Hyperinflation Respiratory Therapies in Cardiac Surgery Patients